ReviewDrugs2015
Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Romosozumab's Effect on Bone Mineral Density in Patients with Osteoporosis: A Systematic Review and Meta-Analysis.Current medicinal chemistry · 2026Pooled it
- Perturbations in gut microbiota composition in osteoporosis: a systematic review and meta-analysis.Journal of bone and mineral metabolism · 2024Pooled it
- Effect of physical therapy on bone remodelling in preterm infants: a multicenter randomized controlled clinical trial.BMC pediatrics · 2022Trial
- Chronic Fluoride Exposure from Brick Tea Consumption Disrupts Bone Remodeling and Contributes to Bone Loss in Chinese Population with Skeletal Fluorosis.Biological trace element research · 2026Article
- Dual-Functional Gel-Based Delivery of Chitosan-Coated Gold Nanoparticles for Accelerated Bone Healing in Defect Models.Pharmaceutics · 2026Article
- Curcumin-preconditioned bone marrow mesenchymal stem cell exosomes ameliorate postmenopausal osteoporosis by activating mitophagy in osteoblast-lineage cells.Frontiers in cell and developmental biology · 2026Article
- Pregnane X receptor protects against age-related bone loss in males via PI3K/Akt-mediated inhibition of apoptosis.Cell death discovery · 2025Article
- A multifunctional self-assembled hydrogel with bactericidal activity and macrophage metabolic reprogramming for diabetic bone defect repair.Materials today. Bio · 2025Article
- Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future.Pharmaceuticals (Basel, Switzerland) · 2025Review
- COPB1 deficiency triggers osteoporosis with elevated iron stores by inducing osteoblast ferroptosis.Journal of orthopaedic translation · 2025Article
- Scorpion-Centipede extracts mitigate ovariectomy-induced osteoporosis in mice through facilitating Cx3cr1 expression.Frontiers in pharmacology · 2025Article
- Article
- Puerarin alleviates osteoporosis in rats by targeting the JAK2/STAT3 signaling pathway.Biomolecules & biomedicine · 2024Article
- Long-term second-generation antipsychotics decreases bone formation and resorption in male patients with schizophrenia.Psychopharmacology · 2024Article
- Extracellular Vesicles from Human Adipose Tissue-Derived Mesenchymal Stem Cells Suppress RANKL-Induced Osteoclast Differentiation via miR122-5p.Biochemical genetics · 2024Article
- Cirsilineol inhibits RANKL-induced osteoclast activity and ovariectomy-induced bone loss via NF-κb/ERK/p38 signaling pathways.Chinese medicine · 2024Article
- [Zinc finger protein-36 deficiency inhibits osteogenic differentiation of mouse bone marrow-derived mesenchymal stem cells and preosteoblasts by activating the ERK/MAPK pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- E3 ubiquitin ligases: key regulators of osteogenesis and potential therapeutic targets for bone disorders.Frontiers in cell and developmental biology · 2024Review
- Therapeutic Efficacy of Medicinal Plants with Allopathic Medicine in Musculoskeletal Diseases.International journal of plant, animal and environmental sciences · 2024Article
- Modulation of the vitamin D/vitamin D receptor system in osteoporosis pathogenesis: insights and therapeutic approaches.Journal of orthopaedic surgery and research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone remodeling, the fundamental process for bone renewal, is targeted by treatments of osteoporosis to correct the imbalance between bone resorption and bone formation and reduce the risk of fractures and associated clinical consequences. Currently available therapeutics affect bone resorption and bone formation in the same direction and either decrease (inhibitors of bone resorption) or increase (parathyroid hormone [PTH] peptides) bone remodeling. Studies of patients with rare bone diseases and genetically modified animal models demonstrated that bone resorption and bone formation may not necessarily be coupled, leading to identification of molecular targets in bone cells for the development of novel agents for the treatment of osteoporosis. Application of such agents to the treatment of women with low bone mass confirmed that bone resorption and bone formation can be modulated in different directions and so far two new classes of therapeutics for osteoporosis have been defined with distinct mechanisms of action. Such treatments, if combined with a favorable safety profile, will offer new therapeutic options and will improve the management of patients with osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.